chidamide + PD-L1 inhibitor + carboplatin + etoposide

This combination therapy regimen consists of the selective histone deacetylase (HDAC) inhibitor chidamide (also known as tucidinostat), an unspecified PD-L1 checkpoint inhibitor, and the cytotoxic chemotherapy doublet of carboplatin and etoposide. It is currently being evaluated by China Medical University as a first-line treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC). Chidamide, a benzamide-class HDAC inhibitor, is intended to epigenetically modulate the tumor microenvironment and enhance the efficacy of immunotherapy by increasing tumor antigenicity and regulating immune cell function. The regimen typically involves an induction phase of four cycles followed by a maintenance phase with chidamide and the PD-L1 inhibitor.

Other names

Chidamide combined with PD-L1 inhibitor and chemotherapyTucidinostat + PD-L1 inhibitor + carboplatin + etoposide